The FDA approved Argos Therapeutics' a revised Special Protocol Assessment (SPA) for its Phase III clinical study of AGS-003 for the treatment of metastatic renal cell carcinoma, or kidney cancer.
Bristol-Myers Squibb was out early Saturday with positive data on BMS-936558, its anti-PD-1 drug obtained in its buyout of Medarex.
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Aiming at a regulatory filing for the experimental kidney cancer drug tivozanib later this year, Aveo Pharmaceuticals ($AVEO) unveiled a slate of late-stage data this morning designed to help build
Knowing your enemy helps to defeat it. Researchers at the Van Andel Research Institute in Michigan kept that in mind with two separate studies that have helped unlock some secrets of certain kidney
Researchers at the Society of Nuclear Medicine in San Antonio, TX, are zapping kidney cancer cells with "smart bombs" made of a new form of radioimmunotherapy that zeroes in on antigens associated
Stanford University researcher Amato Giacci has been working on a new approach to killing cancer cells called synthetic lethality. His lab has been seeking small molecules that target renal cells
Another victory for Pfizer in the U.K. The National Institute for Health and Clinical Excellence once again decided against three kidney cancer drugs, leaving Pfizer's Sutent as the only cutting-edge
Roche's Avastin got FDA approval for the most common type of kidney cancer, based on a study showing that patients on the drug in combination with intereron alpha lived nearly twice as long without
The FDA has approved Novartis' Afinitor (everolimus) to treat the most common kind of kidney cancer. And analysts predict that the drug is on track to become a blockbuster, with new approvals for